Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
eye disease
Biotech
Roche axes Carmot obesity asset, 3 cancer drugs in R&D clear-out
Roche has axed one of the obesity assets from its Carmot buyout months after hyping its potential to drive weight loss past the GLP-1 plateau.
Nick Paul Taylor
Jul 24, 2025 5:00am
Cloudbreak plots phase 3 after eye drop passes midstage test
Jul 21, 2025 4:35am
Okyo's eye drops reduce neuropathic eye pain in phase 2 win
Jul 16, 2025 11:57am
Glaukos nets EU green lights for glaucoma surgery micro-stents
Jun 27, 2025 1:55pm
Atsena gene therapy hits safety goals, closes retinal splits
May 19, 2025 12:59pm
Beacon shines a light on positive early data from eye disease ph. 2
May 7, 2025 7:15am